ArticleAngiogenesis2018
Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro.
Article in Angiogenesis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Organotypic primary blood vessel models of clear cell renal cell carcinoma for single-patient clinical trials.Lab on a chip · 2020Trial
- Engineering Multiscale Vasculature: Biological Principles, Design Constraints, and Advanced Biofabrication Strategies for Functional Vascular Networks.Biomimetics (Basel, Switzerland) · 2026Review
- Nintedanib Attenuates Epidural Fibrosis after Laminectomy in Rats.Journal of Korean Neurosurgical Society · 2026Article
- Dysregulated metabolic pathways of pulmonary fibrosis and the lipids associated with the effects of nintedanib therapy.Respiratory research · 2025Article
- CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data.Oncogene · 2025Article
- Review
- Multiscale computational model predicts how environmental changes and treatments affect microvascular remodeling in fibrotic disease.PNAS nexus · 2025Article
- Barrier-free, open-top microfluidic chip for generating two distinct, interconnected 3D microvascular networks.Scientific reports · 2024Article
- Vascularized organoid-on-a-chip: design, imaging, and analysis.Angiogenesis · 2024Review
- Advancements in preclinical human-relevant modeling of pulmonary vasculature on-chip.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2024Review
- Multiscale computational model predicts how environmental changes and drug treatments affect microvascular remodeling in fibrotic disease.bioRxiv : the preprint server for biology · 2024Article
- Assessing the metastatic potential of circulating tumor cells using an organ-on-chip model.Frontiers in bioengineering and biotechnology · 2024Article
- Mammary Microvessels are Sensitive to Menstrual Cycle Sex Hormones.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Innovative three-dimensional models for understanding mechanisms underlying lung diseases: powerful tools for translational research.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Building Blood Vessel Chips with Enhanced Physiological Relevance.Advanced materials technologies · 2023Article
- Integration of immune cells in organs-on-chips: a tutorial.Frontiers in bioengineering and biotechnology · 2023Review
- Clinical Translation of Engineered Pulmonary Vascular Models.Advances in experimental medicine and biology · 2023Article
- Microfluidics in vascular biology research: a critical review for engineers, biologists, and clinicians.Lab on a chip · 2022Review
- Nintedanib Inhibits Endothelial Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis via Focal Adhesion Kinase Activity Reduction.International journal of molecular sciences · 2022Article
- Transforming Capillary Alginate Gel (Capgel) into New 3D-Printing Biomaterial Inks.Gels (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis is characterized by a progressive scarring and stiffening of the peripheral lung tissue that decreases lung function. Over the course of the disease, the lung microvasculature undergoes extensive remodeling. There is increased angiogenesis around fibrotic foci and an absence of microvessels within the foci. To elucidate how the anti-fibrotic drug nintedanib acts on vascular remodeling, we used an in vitro model of perfusable microvessels made with primary endothelial cells and primary lung fibroblasts in a microfluidic chip. The microvasculature model allowed us to study the impact of nintedanib on permeability, vascularized area, and cell-cell interactions. The anti-vasculogenic impact of nintedanib was visible at the minimal concentrations of 10 nM, showing a significant increase in vessel permeability. Furthermore, nintedanib decreased microvessel density, diameter, and influenced fibroblast organization around endothelial microvessels. These results show that nintedanib acts on the endothelial network formation and endothelial-perivascular interactions. Advanced in vitro microvasculature models may thus serve to pinpoint the mechanistic effect of anti-fibrotic drugs on the microvascular remodeling in 3D and refine findings from animal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.